Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014, 40(5):657-68.

Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks

Chang HW, Tartaglia LJ, Whitney JB, Lim SY, Sanisetty S, Lavine CL, Seaman MS, Rademeyer C, Williamson C, Ellingson-Strouss K, Stamatatos L, Kublin J, Barouch DH. Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J. Virol. 2015, 89(4):1965-74.

Modeling HCV disease in animals: Virology, immunology, and pathogenesis of HCV and GBV-B infections.

Manickam, C. and Reeves, R. K. 2014. Modeling HCV disease in animals: Virology, immunology, and pathogenesis of HCV and GBV-B infections. Front. Microbiol. 5:690. PMID: 25538700. PMCID: PMC4259104

The canarypox vector ALVAC induces distinct cytokine responses compared to the vaccinia-based vectors MVA and NYVAC in rhesus monkeys.

Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. The canarypox vector ALVAC induces distinct cytokine responses compared to the vaccinia-based vectors MVA and NYVAC in rhesus monkeys. J. Virol. 2014; 88:1809-1814.

CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.

Jost S, Tomezsko PJ, Rands K, Toth I, Lichterfeld M, Gandhi RT, Altfeld M. CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination. (2014) J Virol. 88(15):8349- 54.

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2014, 88(5):2489-507.

Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1.

McCoy LE, Rutten L, Frampton D, Anderson I, Granger L, Bashford-Rogers R, Dekkers G, Strokappe NM, Seaman MS, Koh W, Grippo V, Kliche A, Verrips T, Kellam P, Fassati A, Weiss RA. Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog. 2014, 10(12):e1004552.

The immune space: a concept and template for rationalizing vaccine development.

Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI. The immune space: a concept and template for rationalizing vaccine development. AIDS Res. Hum. Retroviruses 2014; 30:1017-1022.

Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer.

Nkolola JP, Bricault CA, Cheung A, Shields J, Perry J, Kovacs JM, Giorgi E, van Winsen M, Apetri A, Brinkman-van der Linden EC, Chen B, Korber B, Seaman MS, Barouch DH. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J. Virol. 2014; 88:9538-9532.

Hexon hypervariable region-modified adenovirus 5 vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.

Teigler JE, Penaloza-MacMaster P, Obeng R, Provine NM, Larocca RA, Borducchi EN, Barouch DH. Hexon hypervariable region-modified adenovirus 5 vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors. Clin. Vaccine Immunol. 2014; 21:1137-1144.